22:37 , May 29, 2019 |  BC Extra  |  Company News

CHMP against Emmaus' sickle cell therapy, Taiwan Liposome's doxorubicin

EMA's CHMP issued several opinions Wednesday, including a negative opinion for Emmaus' sickle cell disease therapy, and on re-examination, a negative recommendation for Taiwan Liposome's breast and ovarian cancer treatment. The agency recommended against approval...
17:39 , Apr 20, 2018 |  BioCentury  |  Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: ATPase Cu++ transporting β polypeptide (ATP7B)

Endocrine/metabolic disease INDICATION: Wilson's disease Patient sample and rat studies suggest the bacterial peptide methanobactin could help treat Wilson's disease, in which ATP7B deficiency results in pathological accumulation of copper in the liver. In hepatocyte...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer BRAF; solute carrier family 31 copper transporters member 1 (SLC31A1; CTR1) Cell culture and mouse studies suggest copper chelation could help treat cancers with...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

EffRx, Kadmon deal

Drug delivery company EffRx will develop effervescent formulations of products to be developed by Kadmon in adult and pediatric Orphan indications. Kadmon has rights from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Montreal, Quebec) to co-commercialize...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

Kadmon, Valeant Pharmaceuticals sales and marketing update

Valeant's Valeant Pharmaceuticals North America LLC subsidiary granted Kadmon's Kadmon Pharmaceuticals LLC subsidiary U.S. co-commercialization rights to Syprine trientine capsules. The chelating compound is approved to treat patients with Wilson's disease who are intolerant of...
08:00 , Nov 13, 2006 |  BC Week In Review  |  Clinical News

Coprexa: Pivotal trial data

In a double-blind, pivotal trial in 48 patients, Coprexa met the primary endpoint of a statistically significant reduction in incidence of neurologic worsening vs. Syprine trientine (4% vs. 26%, p<0.05). Patients received Galzin zinc acetate...